GENF.L
Genflow Biosciences plc
1W: -7.1%
1M: -3.2%
3M: -8.0%
YTD: -12.4%
1Y: -4.7%
3Y: -14.4%
£1.80 ($0.02)
-0.05 (-2.70%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap£9.9M ($0.1M)
52W Range0.55-2.7
Volume363,715
Avg Volume2,205,412
Beta2.24
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOEric Jean Leire
Employees5
SectorHealthcare
IndustryBiotechnology
IPO Date2022-01-17
Websitegenflowbio.com
15 Ingestre Place
London W1F 0DU
GB
London W1F 0DU
GB
44 32 4774 95881
About Genflow Biosciences plc
Genflow Biosciences plc operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing or halting the ageing process, and reducing the incidence of age-related diseases with increase in health span. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. The company was incorporated in 2021 and is headquartered in London, the United Kingdom.
Latest News
Genflow Biosciences (LON:GENF) Stock Price Down 6.3% – Time to Sell?
Genflow Biosciences: AGM and partnership strategy - ICYMI
Nasdaq leads market declines as AI concerns weigh on tech stocks
AI-driven market disruption could hit loans and high-yield credit, UBS says
Pri0r1ty Intelligence shares rise as it launches new AI product
Recent Insider Trades
No insider trades found